Morgan Stanley analyst David Lebowitz upgraded Ironwood to Equal Weight from Underweight, citing his view that Linzess growth will stabilize after multiple quarters of deceleration. The withdrawal of generic MiraLAX in November 2018 will bring new patients in the near-term and new Phase 3 data expected by mid year should allow for new claims of reducing pain, discomfort and bloating, which Lebowitz thinks will bring new patients on board and help sales. Additionally, the company's spinoff of Cyclerion, expected to be completed on April 1, should lower costs and contribute to profitability, the analyst said. He raised his price target on Ironwood shares to $14 from $11.